implants - international magazine of oral implantology International Edition

I 49implants1_2014 NEWS Theglobalmarketfordentalimplants and prostheses is estimated to be worth $9.1 billion by 2018, Market- sandMarkets, a US-based market research and consulting company, has announced.This means a 30 per cent increase compared to 2013, whenthemarketwasestimatedtobe worth $6.4 billion. The market is drivenmainlybytherisingedentulous population,increasingadoptionofad- vanced dentistry in developed coun- tries,theincreaseindisposableincomes,andincreas- ingawarenessofdentalcare. Despitetheincrease,theeconomicslowdownandlim- itedreimbursementarefactorsthatinhibitthegrowth of the market to a certain extent, the company ex- plained in a press release. Despite competitive pres- sure from local players, the key contributors are ex- pected to retain their leading positions in the global market.This is primarily supported by con- tinuous investment by these companies in research and development and by their strong global presence. Therefore, the top three companies are expected to maintain theirpositionswitharound50percentshare ofthedentalimplantsmarketinthenextfew years. The major players in this market in- cludeLiechtenstein-basedIvoclarVivadent, Swiss companies Nobel Biocare and Straumann, as well as US manufacturers DENTSPLY International, Zimmer Dental, BIOMET3i,BioHorizonsand3M. The complete report, titled "Dental Implants & Pros- theticsMarket(Implants,Crowns&Bridges,Dentures, Abutments) Current Trends, Opportunities & Global Forecasts to 2018," which discusses the key market drivers,restraints,and opportunities of the global im- plants and prostheses market,as well as its submar- kets,canbepurchasedonline. Dental implants and prostheses Market worth more than $9 billion by 2018 About 6 to 15 per cent of patients suffer from peri- implantitis,inflammationthatdestroyssoftandhard tissue surrounding the implant after placement.It is known that the concentration of matrix metallopro- teinase-8,anenzymethatisalsoresponsibleforpe- riodontitis, increases significantly when inflamma- tion around the dental implant arises. Prof. Lorenz Meinel from the Institute of Pharmacy and Food Chemistry at the University of Würzburg explained that this increase could be identified through a spe- cialchewinggumusingasmallpeptidechainthatis bound to a bitter-tasting compound. Once enzyme concentrations in a patient’s saliva exceed a certain level owing to complications with the implant, the peptide chain will snap, releasing the bitter com- pound. In the future, special chewing gum could be part of post-operative care in addition to routine check-ups.Patientswouldhavetocontacttheirden- tist upon recognising the bitter taste. In addition to the development of the chewing gum, the researchers are considering developing a coat- ing that uses the peptide chain system and can be applied to the implant directly. The project will be carried out in collaboration with SwissdentalimplantmanufacturerThommenMed- ical and various other European companies and sci- entific institutions.The research has received fund- ing of €1 million for two years from the European Union. Could chewing gum prevent Implant failure in the future? Cluster headache is one of the most severe forms of headache. It is usually unilateral and occurs mostly aroundtheeyeorinthetemple.Attackslastuptosev- eralhours.Inmanypeople,clusterheadacheleadstoa significant loss of quality of life.A new type of cluster headache treatment is the stimulation of the sphenopalatineganglion(SPG).TheATINeurostimula- tion System stimulates the SPG in order to break the paincycle.Theneurostimulator,whichisthesizeofan almond,isinsertedthroughasmallincisioninthegin- giva and programmed by the physician. As cluster headacheoccursunilaterally,theimplantisinsertedon therelevantside.Thesurgeryisperformedundergen- eralanaestheticandtakesaboutanhour. The patient can control his or her therapy independ- entlyviaaremotecontrol.Whenaclusterattackoccurs, heorsheholdsthedeviceagainstthecheektoactivate theimplant.ThisstimulatestheSPGandabatestheat- tack. In many patients, the frequency of attacks de- creasespermanently. The effectiveness of theATI Neurostimulation System hasbeenclinicallyproveninthemostcomprehensive medical study on cluster headache.With theATI neu- rostimulator,82percentofallattacks—evenmedium to severe—can be treated effectively, the manufac- turer,AutonomicTechnologies,stated.In46percentof patients, the attack frequency was reduced signifi- cantly—fromanaverageof14downtotwoattacksper week.The ATI Neurostimulation System has been in- troducedatnineclinicsinGermanyandisinuseinBel- gium. Gingival implant supports Reduction of cluster headache [PICTURE:©3DPICTURES] [PICTURE: ©OLLYY] [PICTURE: ©OLLYY]